DNLI - Company ID 0001714899
The table below shows Denali Therapeutics Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q3 2026 | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Revenue | $17.78M | $3.60M | - | $0.00 | $0.00 | - |
| Cost of revenue | $192.00K | $93.00K | - | $0.00 | $0.00 | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $106.10M | $97.02M | $103.85M | $101.95M | $102.70M | $116.23M |
Denali Therapeutics Inc. reported annual revenue of $0.00 for fiscal year 2025. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $37.48M |
| $36.28M |
| $33.51M |
| $35.48M |
| $32.27M |
| $29.35M |
| Operating income | -$126.75M | -$130.54M | -$137.36M | -$137.43M | -$134.96M | -$145.58M |
| Income tax | - | - | - | - | - | - |
| Net income | $70.13M | -$127.55M | -$128.45M | -$126.90M | -$124.12M | -$132.97M |
| EPS (diluted) | $0.37 | -$0.68 | -$0.69 | -$0.74 | -$0.72 | -$0.78 |